September 13, 2019

Kai Haakon E. Liekefett, Esq.
Sidley Austin LLP
787 Seventh Avenue
New York, NY 10019

       Re:     AMAG Pharmaceuticals, Inc.
               Preliminary Consent Revocation Statement
               Filed September 10, 2019
               File No. 001-10865

               Soliciting Materials Files Pursuant to Exchange Act Rule 14a-12
               Filed September 12, 2019
               File No. 001-10865

Dear Mr. Liekefett:

       We have reviewed the filing above and have the following comments. In
some of our
comments, we may ask you to provide us with information so we may better
understand the
disclosure.

       Please respond to this letter by amending the filing or by providing the
requested
information. If you do not believe our comments apply to the Company's facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

         After reviewing any amendment to the filing and the information you
provide in response
to this comment, we may have additional comments. All defined terms used in
this letter have
the same meaning as in the preliminary consent revocation statement unless
otherwise indicated.

Consent Revocation Statement

Q: Why Am I Receiving This Consent Revocation Statement? Page 1

1.     Please revise the disclosure here and throughout the consent revocation
statement to
       reference the actual date, June 21, 2019, that Caligan became a
stockholder.

Q: What Should I Do to Revoke My Consent..., page 2

2.     Disclosure in this paragraph includes the phrase "REVOKE MY REQUEST." It
appears
       the intention was to refer to "REVOKE MY CONSENT." Please advise.
 Kai Haakon E. Liekefett, Esq.
Sidley Austin LLP
September 13, 2019
Page 2

Q: What is the Effect of Delivering a Green Consent Revocation Card? Page 2

3.     Please revise the disclosure here and on the consent revocation card
itself to indicate the
       effect of marking "Do Not Revoke My Consent," including the effect such
action has on
       a previously submitted consent.

4.     Please revise the disclosure to indicate the legal basis for why an
"Abstain" vote would
       have the effect of revoking a consent.

Reasons to Reject the Caligan Proposals, page 5

5.     Disclosure indicates that the Company recommends the rejection of
Proposal 4 because
       "we do not believe that indefinitely capping the size of the Board of
Directors is clearly
       in the best interests of our stockholders." It is our understanding that
the size of the Board
       is not capped "indefinitely." For example, if Proposal 4 passes, the
Board size can be
       increased by a majority of the outstanding stockholder vote or by the
Board (whether or
       not Proposal 5 passes). Please revise or advise.

Form of Consent Revocation

6.     Please refer to the following disclosure: "If no box is marked for a
proposal, the
       undersigned will be treated as having revoked its consent...." Please
revise this
       statement to conform to the standards specified in Exchange Act Rule
14a-4(b), or
       advise.

Soliciting Materials Files Pursuant to Exchange Act Rule 14a-12

7.     The included press release contains the statement "...[the Company] is
concerned that
       certain actions pushed by Caligan may be destructive to the long-term
value of the
       Company." Please identify such actions and provide support for such
opinion or refrain
       from making such generalized statements in future filings.

                                            *    *    *

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.
 Kai Haakon E. Liekefett, Esq.
Sidley Austin LLP
September 13, 2019
Page 3

       Please contact me at (202) 551-3444 with any questions.

                                                          Sincerely,

                                                          /s/ Perry J. Hindin

                                                          Perry J. Hindin
                                                          Special Counsel
                                                          Office of Mergers and
Acquisitions